This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Van Ameringen, M. Articles by Bennett, M. Search for Related Content PubMed PubMed Citation Articles by Van Ameringen, M. Articles by Bennett, M. Social Bookmarking                   What's this?

Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series

Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada, vanamer{at}mcmaster.ca

Catherine Mancini

Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada

Beth Patterson

Anxiety Disorders Clinic, McMaster University Medical Centre, HHS, Hamilton, Ontario, Canada

Mark Bennett

Anxiety Disorders Clinic, McMaster University Medical Centre, HHS, Hamilton, Ontario, Canada

Generic agents do not require large clinical trials of safety and efficacy to enter the market, although they must demonstrate both pharmacological and bioequivalence to the brand name drug. BioequivaLence is attained when the extent of absorption of the generic falls within an FDA predefined range relative to the brand name drug. This potential variation in bioequivalence is not thought to be clinically meaningful, however, there are reports of a lack of therapeutic equivalence between some generic medications and the brand name. This study examines the potential risks posed by a switch from Celexa to generic citalopram. Twenty patients at an Anxiety Disorders Clinic who were unknowingly switched to generic citalopram, from Celexa (Lundbeck, Montreal, Quebec, Canada) and experienced a re-emergence of their anxiety symptoms or development of new adverse events are described in this case series report. The mean time for re-emergence of symptoms or development of adverse events was 3.4 ± 1.6 weeks (range 0.5—8 weeks). All patients reestabLished previous treatment response with a change back to Celexa in a mean time of 3.8 ± 2.6 weeks (range 0.7—12 weeks). Given these results, it is important for clinicians to be aware of the potentiaL for loss of treatment effect or symptom re-emergence posed by a switch to a generic agent. Randomized, doubLe blind, controlled investigations would likely provide useful information as current bioequivalence and pharmacological equivalence do not necessarily translate into clinical equivalence.

Key Words: citalopram • generic drugs • therapeutic equivalency • recurrence (symptom) • anxiety disorders • adverse effects

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. Blier Generic medications: another variable in the treatment of illnesses J Psychopharmacol, July 1, 2007; 21(5): 459 - 460. [PDF]